$AMWD

Insider Buying week 12-03-21 -Let me Count the Ways I Hate SPACS

by

Curious how well insiders are doing with their buys? Click on this link or image above to scroll the significant buys of the last year. I’ve been monitoring insider behavior and how it impacts stock prices for about as long as anyone out there I haven’t seen much that shocks me or changes my perception of the usefulness of this information.  Now I have.  Normally significant insider buying will put a floor on a down-trending stock.  That’s changed with SPACS.  No matter how encouraging the news is or robust the insider buying is, when you have big shareholders waiting in … Read more

The Bold, the Inexplicable and the Good Soldiers- Insider Buying Week 9-17-21

by

For trade, details click on this link to the trades.  There were quite a few buys last week and it took me longer than usual to update it. Also, I will provide a brief recap of the conversation I had with the Chief Medical Officer, Alexander A. Zukiwski at Casi Pharmaceuticals. Casi is a U.S. NASDAQ-listed biotech selling exclusively to the increasingly affluent Chinese middle class.  CASI is a penny stock that will turn into $dollars if things pan out the way I think. They have one approved revenue-producing product with an exciting pipeline. There is a high probability they … Read more

”t forget the Covid-19 test kit $QDEL Insider Buying Week of 6-19-20

by

These are the insider buys that matter for last week. For real time insider alerts subscribe to our Twitter at https://twitter.com/theinsidersfund.  When insiders buy, stocks make knee jerk moves up. The best time period to make bank is the next three days, perhaps five and then the prior trend sets in.  Follow us on Twitter for the names we take an interest in. This week’s top movers are Camping World Holdings up 27.03% and Quidel, up 29.88% The average 3 day gain was 5.25% and holding just three days longer pushed it to 8.04%.  If there is no 5 day … Read more

What are Insiders Buying at Market Highs- Week 6-12-20?

by

Fibrogen CEO Conterno bought 27,800 shares at $35.47.  After last year’s unexpected passing of founder and long-time helmsman Thomas Neff, FibroGen needed a permanent successor—and with its big roxadustat launch looming, that new CEO would ideally know the ropes in kidney and metabolic diseases. Conterno, who came from Lilly six months ago as its U.S. business chief and worldwide diabetes lead, became FibroGen’s new CEO, in January. This is his first open market purchase.  Here is a link to a  recent Goldman Sachs investor presentation According to their website, FGEN is dedicated to creating innovative, first-in-class medicines for the treatment … Read more